Jason D. Wright, MD

Articles by Jason D. Wright, MD

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

ByMargaret I. Liang, MD, MS,Ling Chen, MD, MPH,Emeline M. Aviki, MD, MBA,Jason D. Wright, MD

March 1st 2024

Among a cohort of insured patients with cancer, the median total monthly cost of oral lenvatinib was $17,253, and 75% of patients paid $100 or less out of pocket per month for the drug.

Latest Updated Articles

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients
Published: March 1st 2024 | Updated:

Jason D. Wright, MD

Articles by Jason D. Wright, MD

Cost Sharing for Oral Lenvatinib Among Commercially Insured Patients

Latest Updated Articles

Trending on AJMC

Withdrawal of Aid Could Cause Millions of Lives Lost to HIV

EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy

Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color

Mortality Gap Between Puerto Rico and the US Mainland Among Medicare Advantage Enrollees

FDA Approves Second Generic Mifepristone Pill for Abortion